Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2018-10, Vol.29, p.viii461-viii462 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | viii462 |
|---|---|
| container_issue | |
| container_start_page | viii461 |
| container_title | Annals of oncology |
| container_volume | 29 |
| creator | Owonikoko, T.K. Papadopoulos, K.P. Gil-Martin, M. Moreno, V. Salama, A.K. Calvo, E. Safran, H. González-Martín, A. Aljumaily, R. Mahadevan, D. Niu, J. Kal Mohan, K. Li, J. Stankevich, E. Mathias, M. Lowy, I. Fury, M.G. Babiker, H.M. |
| description | |
| doi_str_mv | 10.1093/annonc/mdy289.048 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdy289_048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419497470</els_id><sourcerecordid>32137181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2788-c62d9bc021cc63205faf190ff0cbb36ede70420343f255f375ec7b481354c84c3</originalsourceid><addsrcrecordid>eNp9kctu1TAQhiMEoofCA7BBswSpae04V1ihcKt0JCoB62gyGXOMHDvETqs8Iy9FqgBLVjOL-X6N_i9JnktxKUWjrtA57-hqHNasbi5FXj9IDrIom7QWuXyYHESTqbQqVH6WPAnhhxCibLLmcXKmMqkqWctD8uvmhIHhGkJchhW8BuLRTNaM2F8AwmkZ0cHonSfrHVpAF0168y6VF2AcTBgNuxjgzsQTLG7mwBSxtwzWE1q7Ag636IgH8DOMHDHEjSGgJaJjvwQIPxcc7xdia4FwJuP8iPCy_dK2r17D0bvvPIP21vq7dJmAtTaEtEW7AQJqjisMGPFp8kijDfzszzxPvn14_7X9lB4_f7xu3x5Tyqq6TqnMhqYnkUmiUmWi0KhlI7QW1Peq5IErkWdC5UpnRaFVVTBVfV5LVeRU56TOE7nn0uxDmFl307z1Na-dFN29mG4X0-1iuk3MxrzYmWnpRx7-EX9NbAdv9gPePr81PHeBtmq34sy8VdoN3vwn_jdRFKSD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data</title><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Owonikoko, T.K. ; Papadopoulos, K.P. ; Gil-Martin, M. ; Moreno, V. ; Salama, A.K. ; Calvo, E. ; Safran, H. ; González-Martín, A. ; Aljumaily, R. ; Mahadevan, D. ; Niu, J. ; Kal Mohan, K. ; Li, J. ; Stankevich, E. ; Mathias, M. ; Lowy, I. ; Fury, M.G. ; Babiker, H.M.</creator><creatorcontrib>Owonikoko, T.K. ; Papadopoulos, K.P. ; Gil-Martin, M. ; Moreno, V. ; Salama, A.K. ; Calvo, E. ; Safran, H. ; González-Martín, A. ; Aljumaily, R. ; Mahadevan, D. ; Niu, J. ; Kal Mohan, K. ; Li, J. ; Stankevich, E. ; Mathias, M. ; Lowy, I. ; Fury, M.G. ; Babiker, H.M.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy289.048</identifier><identifier>PMID: 32137181</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Annals of oncology, 2018-10, Vol.29, p.viii461-viii462</ispartof><rights>2018 THE AUTHORS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2788-c62d9bc021cc63205faf190ff0cbb36ede70420343f255f375ec7b481354c84c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32137181$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Owonikoko, T.K.</creatorcontrib><creatorcontrib>Papadopoulos, K.P.</creatorcontrib><creatorcontrib>Gil-Martin, M.</creatorcontrib><creatorcontrib>Moreno, V.</creatorcontrib><creatorcontrib>Salama, A.K.</creatorcontrib><creatorcontrib>Calvo, E.</creatorcontrib><creatorcontrib>Safran, H.</creatorcontrib><creatorcontrib>González-Martín, A.</creatorcontrib><creatorcontrib>Aljumaily, R.</creatorcontrib><creatorcontrib>Mahadevan, D.</creatorcontrib><creatorcontrib>Niu, J.</creatorcontrib><creatorcontrib>Kal Mohan, K.</creatorcontrib><creatorcontrib>Li, J.</creatorcontrib><creatorcontrib>Stankevich, E.</creatorcontrib><creatorcontrib>Mathias, M.</creatorcontrib><creatorcontrib>Lowy, I.</creatorcontrib><creatorcontrib>Fury, M.G.</creatorcontrib><creatorcontrib>Babiker, H.M.</creatorcontrib><title>Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kctu1TAQhiMEoofCA7BBswSpae04V1ihcKt0JCoB62gyGXOMHDvETqs8Iy9FqgBLVjOL-X6N_i9JnktxKUWjrtA57-hqHNasbi5FXj9IDrIom7QWuXyYHESTqbQqVH6WPAnhhxCibLLmcXKmMqkqWctD8uvmhIHhGkJchhW8BuLRTNaM2F8AwmkZ0cHonSfrHVpAF0168y6VF2AcTBgNuxjgzsQTLG7mwBSxtwzWE1q7Ag636IgH8DOMHDHEjSGgJaJjvwQIPxcc7xdia4FwJuP8iPCy_dK2r17D0bvvPIP21vq7dJmAtTaEtEW7AQJqjisMGPFp8kijDfzszzxPvn14_7X9lB4_f7xu3x5Tyqq6TqnMhqYnkUmiUmWi0KhlI7QW1Peq5IErkWdC5UpnRaFVVTBVfV5LVeRU56TOE7nn0uxDmFl307z1Na-dFN29mG4X0-1iuk3MxrzYmWnpRx7-EX9NbAdv9gPePr81PHeBtmq34sy8VdoN3vwn_jdRFKSD</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Owonikoko, T.K.</creator><creator>Papadopoulos, K.P.</creator><creator>Gil-Martin, M.</creator><creator>Moreno, V.</creator><creator>Salama, A.K.</creator><creator>Calvo, E.</creator><creator>Safran, H.</creator><creator>González-Martín, A.</creator><creator>Aljumaily, R.</creator><creator>Mahadevan, D.</creator><creator>Niu, J.</creator><creator>Kal Mohan, K.</creator><creator>Li, J.</creator><creator>Stankevich, E.</creator><creator>Mathias, M.</creator><creator>Lowy, I.</creator><creator>Fury, M.G.</creator><creator>Babiker, H.M.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201810</creationdate><title>Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data</title><author>Owonikoko, T.K. ; Papadopoulos, K.P. ; Gil-Martin, M. ; Moreno, V. ; Salama, A.K. ; Calvo, E. ; Safran, H. ; González-Martín, A. ; Aljumaily, R. ; Mahadevan, D. ; Niu, J. ; Kal Mohan, K. ; Li, J. ; Stankevich, E. ; Mathias, M. ; Lowy, I. ; Fury, M.G. ; Babiker, H.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2788-c62d9bc021cc63205faf190ff0cbb36ede70420343f255f375ec7b481354c84c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Owonikoko, T.K.</creatorcontrib><creatorcontrib>Papadopoulos, K.P.</creatorcontrib><creatorcontrib>Gil-Martin, M.</creatorcontrib><creatorcontrib>Moreno, V.</creatorcontrib><creatorcontrib>Salama, A.K.</creatorcontrib><creatorcontrib>Calvo, E.</creatorcontrib><creatorcontrib>Safran, H.</creatorcontrib><creatorcontrib>González-Martín, A.</creatorcontrib><creatorcontrib>Aljumaily, R.</creatorcontrib><creatorcontrib>Mahadevan, D.</creatorcontrib><creatorcontrib>Niu, J.</creatorcontrib><creatorcontrib>Kal Mohan, K.</creatorcontrib><creatorcontrib>Li, J.</creatorcontrib><creatorcontrib>Stankevich, E.</creatorcontrib><creatorcontrib>Mathias, M.</creatorcontrib><creatorcontrib>Lowy, I.</creatorcontrib><creatorcontrib>Fury, M.G.</creatorcontrib><creatorcontrib>Babiker, H.M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Owonikoko, T.K.</au><au>Papadopoulos, K.P.</au><au>Gil-Martin, M.</au><au>Moreno, V.</au><au>Salama, A.K.</au><au>Calvo, E.</au><au>Safran, H.</au><au>González-Martín, A.</au><au>Aljumaily, R.</au><au>Mahadevan, D.</au><au>Niu, J.</au><au>Kal Mohan, K.</au><au>Li, J.</au><au>Stankevich, E.</au><au>Mathias, M.</au><au>Lowy, I.</au><au>Fury, M.G.</au><au>Babiker, H.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>29</volume><spage>viii461</spage><epage>viii462</epage><pages>viii461-viii462</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32137181</pmid><doi>10.1093/annonc/mdy289.048</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2018-10, Vol.29, p.viii461-viii462 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdy289_048 |
| source | Alma/SFX Local Collection; EZB Electronic Journals Library |
| title | Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T19%3A12%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20I%20study%20of%20cemiplimab,%20a%20human%20monoclonal%20anti-PD-1,%20in%20patients%20with%20unresectable%20locally%20advanced%20or%20metastatic%20cutaneous%20squamous%20cell%20carcinoma%20(CSCC):%20Longer%20follow-up%20efficacy%20and%20safety%20data&rft.jtitle=Annals%20of%20oncology&rft.au=Owonikoko,%20T.K.&rft.date=2018-10&rft.volume=29&rft.spage=viii461&rft.epage=viii462&rft.pages=viii461-viii462&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy289.048&rft_dat=%3Cpubmed_cross%3E32137181%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32137181&rft_els_id=S0923753419497470&rfr_iscdi=true |